E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
What is sarcopenic obesity, and why should Indians look beyond BMI and prioritise muscle health? Dr Chirantan Bose and Dr Preetesh Bhandari, co-founders of VytalYou, explain…
dineshwori
FSSAI has published a draft amendment to the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020, proposing a ban on the addition of sucrose and fructose in foods for infants up to six months.
imphoenix82
Rona Therapeutics enters into a $1.16 billion global licensing agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases.
imphoenix82
Novo Nordisk has licensed HRS-1596, a Phase 1-ready oral GLP-1/GIP dual agonist from Hengrui Pharma, in a deal worth up to $2.6 billion, while new real-world data linked semaglutide 2 mg with a lower risk of major adverse cardiovascular events than switching to tirzepatide
imphoenix82
Novo receives a global licence to use Nanexa’s proprietary ALD-based drug delivery platform for peptide drugs targeting obesity, type 2 diabetes and other cardiometabolic diseases.
imphoenix82
Cardiovascular risk can develop early and often without obvious symptoms. Doctors highlight the health checks young adults should consider to detect potential heart risks early.
imphoenix82
Under the rebrand, ‘Novo’ will be used as the company’s day-to-day name, while Novo Nordisk A/S will remain its legal global company name.
imphoenix82
Researchers suggest that microbiome-based therapies should be tailored to regional populations rather than adopting approaches developed solely from Western populations.
imphoenix82
Amygdala Neurosciences is initially developing ANS-858 as a potential treatment for alcohol use disorder and other substance use disorders.
imphoenix82
The ANVISA GMP certification will help Innogen accelerate the registration and commercial launch of Efsubaglutide alfa across all PIC/S-aligned emerging markets, including Hong Kong, Southeast Asia and Latin America.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
